Literature DB >> 16415891

Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma after cord blood stem cell transplantation following autologous peripheral blood stem cell transplantation.

R Sakai, S Fujisawa, K Fujimaki, H Kanamori, Y Ishigatsubo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16415891     DOI: 10.1038/sj.bmt.1705272

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  5 in total

Review 1.  Hepatosplenic T-cell lymphoma: a rare but challenging entity.

Authors:  Barbara Pro; Pamela Allen; Amir Behdad
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

2.  Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience.

Authors:  Martin H Voss; Matthew A Lunning; Jocelyn C Maragulia; Esperanza B Papadopoulos; Jenna Goldberg; Andrew D Zelenetz; Steven M Horwitz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-10-27

3.  Sustained first remission in an adolescent with hepatosplenic T-cell lymphoma treated with T-cell leukemia induction, nucleoside analog-based consolidation, and early hematopoietic stem cell transplant.

Authors:  Eric Schafer; Allen Chen; Robert J Arceci
Journal:  Pediatr Blood Cancer       Date:  2009-12       Impact factor: 3.167

4.  Successful HLA haploidentical myeloablative stem cell transplantation for aggressive hepatosplenic alpha/beta (αβ) T-cell lymphoma.

Authors:  Gioacchino Catania; Francesco Zallio; Federico Monaco; Maria Teresa Corsetti; Nicol Trincheri; Lisa Bonello; Lia Mele; Franco Dallavalle; Flavia Salvi; Massimo Pini
Journal:  Leuk Res Rep       Date:  2014-10-28

Review 5.  The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma.

Authors:  Susann Schönefeldt; Tamara Wais; Marco Herling; Satu Mustjoki; Vasileios Bekiaris; Richard Moriggl; Heidi A Neubauer
Journal:  Cancers (Basel)       Date:  2021-12-09       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.